Boston Prepares For Robotics Revolution As Summit Brings Together Visionary Thinkers
The 2025 Robotics Summit & Expo is set to become a hub for innovation and technological …
17. June 2025
Pioneering Robotics Paves New Frontier With First-Ever Robotic Cardiac Surgery In The Americas
SS Innovations Makes History with First Robotic Cardiac Surgery in the Americas with SSi Mantra 3 System
In a groundbreaking medical milestone, SS Innovations International Inc., a leading provider of robotic surgical systems, has successfully completed its first cardiac surgery in the Americas using its advanced SSi Mantra 3 system. This remarkable achievement marks a significant milestone in the company’s mission to make robotic surgery more accessible and affordable globally.
The pioneering procedure took place on June 8 at Interhospital in Guayaquil, Ecuador, where renowned cardiothoracic surgeon Dr. Juan Zuniga performed a robotic Atrial Septal Defect (ASD) closure using the SSi Mantra 3 system. This complex surgery repairs a hole between the upper two chambers of the heart, a condition that can lead to serious complications if left untreated.
According to Dr. Zuniga, the experience with the SSi Mantra was overwhelmingly positive, citing the ease of use and manipulation of the robotic arms as key factors in achieving a successful outcome. “The equipment was very easy to handle and manipulate,” he noted. “The results were effective, as we conducted a transesophageal echocardiogram to verify the complete closure of the communication between the two upper chambers of the heart.” The patient is recovering well, with Dr. Zuniga expressing satisfaction with the outcomes.
Interhospital, being the first hospital in South America to install the SSi Mantra, has already performed a variety of complex surgical procedures using this advanced system since its introduction. The versatility and precision offered by the robotic arms have enabled the medical team to perform intricate surgeries with minimal invasiveness, reducing recovery time, bleeding, and complications.
The SSi Mantra 3 system boasts an impressive array of features that make it an ideal tool for complex surgical procedures:
Three to five modular robotic arms for enhanced dexterity An open-faced ergonomic surgeon command center for optimal control A large 3D 4K monitor for immersive visualization A touch panel monitor for all patient-related information displays Virtual real-time image of the robotic patient-side arm carts for seamless coordination The ability to superimpose 3D models for diagnostic imaging, providing surgeons with a more comprehensive understanding of the anatomy
This cutting-edge technology has also been complemented by an extensive range of over 40 types of robotic endo-surgical instruments, catering to diverse specialties, including cardiac surgery. The SSi Mantra system has undergone clinical validation in India and has been successfully used in over 4,000 surgeries worldwide, with approximately 215 cardiac surgical procedures performed.
The recent completion of its first cardiac surgery in the Americas underscores SS Innovations’ commitment to advancing robotic surgery and making it more accessible to a wider audience. The company’s product range includes its proprietary SSi Mantra system and its suite of SSi Mudra instruments, designed to support a wide array of surgical procedures.
As part of its mission to democratize access to robotic surgery, SS Innovations has developed comprehensive systems to make these cutting-edge technologies affordable and inclusive for more patients worldwide. The company’s latest addition, the SSi Mantra 3 system, was released in July 2024 and received regulatory approval for remote surgery and teleproctoring from the Central Drugs Standard Control Organization (CDSCO). This significant milestone enables the potential for remote surgeries and medical education, expanding the reach of robotic surgical capabilities globally.
In a forthcoming development, SS Innovations has announced plans to submit a de novo classification request to the U.S. Food and Drug Administration for the SSi Mantra 3 system, further solidifying its position in the rapidly evolving landscape of robotic surgery.
With each milestone achieved, this trailblazing company reinforces its commitment to transforming medical care and shaping a brighter future for patients worldwide. The SSi Mantra 3 system is poised to revolutionize cardiac surgery, offering unprecedented precision, versatility, and accessibility to surgeons globally.